Literature DB >> 6995552

Role of activated macrophages in antibody-dependent lysis of tumor cells.

C Nathan, L Brukner, G Kaplan, J Unkeless, Z Cohn.   

Abstract

Treatment of mice with Bacille Calmette-Guérin (BCG) or C parvum activates their peritoneal macrophages to release increased amounts of H2O2, and thereby to lyse extracellular tumor cells, in response to a pharmacologic agent, phorbol myristate acetate (PMA) (1-3). In the present study, the same bacterial vaccines activated peritoneal cells to become cytolytic to lymphoma cells sensitized with alloantiserum, in the absence of PMA. Resident peritoneal cells, or those elicited with thioglycollate broth, were ineffective, not only in PMA-induced lysis, but also in antibody-dependent lysis of tumor cells. The cytolytic effect of BCG peritoneal cells toward sensitized tumor cells appeared to be mediated mostly by macrophages. Cytotoxicity was immunologically specific, contact dependent, rapid, and efficient. Phagocytosis of intact tumor cells was not involved. Alloantiserum-dependent cytolysis was specifically blocked by the Fab fragment of a monoclonal antibody directed against the trypsin-resistant macrophage Fc receptor (FcR II). Thus, tumor cells coated with homologous immunoglobulin interact with FcR II on activated macrophages to trigger an extra-cellular cytolytic response.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6995552      PMCID: PMC2185907          DOI: 10.1084/jem.152.1.183

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  43 in total

1.  Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity.

Authors:  R P Gale; J Zighelboim
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

2.  Immunological destruction of herpes simplex virus I infected cells.

Authors:  B Rager-Zisman; B R Bloom
Journal:  Nature       Date:  1974-10-11       Impact factor: 49.962

3.  Evidence for several cell populations active in antibody dependent cellular cytotoxicity.

Authors:  J Zighelboim; B Bonavida; J L Fahey
Journal:  J Immunol       Date:  1973-12       Impact factor: 5.422

4.  Phagocytosis of murine lymphoma cells by macrophages. I. Factors affecting in vitro phagocytosis.

Authors:  R Evans
Journal:  Immunology       Date:  1971-01       Impact factor: 7.397

5.  Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis.

Authors:  I M Goldstein; D Roos; H B Kaplan; G Weissmann
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

6.  Stimulation of human neutrophils by soluble and insoluble immunoglobulin aggregates. Secretion of granule constituents and increased oxidation of glucose.

Authors:  P M Henson; Z G Oades
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

7.  Biological defense mechanisms. The effect of bacteria and serum on superoxide production by granulocytes.

Authors:  J T Curnutte; B M Babior
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

8.  The selective inhibition of macrophage phagocytic receptors by anti-membrane antibodies.

Authors:  P Holland; N H Holland; Z A Cohn
Journal:  J Exp Med       Date:  1972-03-01       Impact factor: 14.307

9.  Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane.

Authors:  F M Griffin; J A Griffin; J E Leider; S C Silverstein
Journal:  J Exp Med       Date:  1975-11-01       Impact factor: 14.307

10.  Antibody-mediated suppression of grafted lymphoma cells. II. Participation of macrophages.

Authors:  H S Shin; N Kaliss; D Borenstein; M K Gately
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  33 in total

1.  A journey in science: promise, purpose, privilege.

Authors:  Carl Nathan
Journal:  Mol Med       Date:  2013-10-03       Impact factor: 6.354

2.  Uptake and utilization of human polymorphonuclear leukocyte granule myeloperoxidase by mouse peritoneal macrophages.

Authors:  K P Leung; M B Goren
Journal:  Cell Tissue Res       Date:  1989-09       Impact factor: 5.249

3.  Shedding and synthesis de novo of Fc and C3b receptors by cultured guinea-pig macrophages.

Authors:  G A Limb; K A Brown; R A Wolstencroft; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

4.  The effect of adherence on the in vitro induction of cytocidal activity by macrophages.

Authors:  A Friedman; D I Beller
Journal:  Immunology       Date:  1987-08       Impact factor: 7.397

Review 5.  Fc receptor--more answers, more questions.

Authors:  L Fornůsek; V Vĕtvicka
Journal:  Folia Microbiol (Praha)       Date:  1984       Impact factor: 2.099

6.  Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.

Authors:  M Nagarkatti; P S Nagarkatti; A M Kaplan
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.

Authors:  M Awwad; P G Strome; S C Gilman; H R Axelrod
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

8.  Murine T cells that lyse antibody-sensitized target cells. III. Contribution of Thy 1-Bearing cells to the lytic activity of normal spleen.

Authors:  E W Lamon; B A Pollok; A S Walia; E W Fuson; B Williams
Journal:  Immunology       Date:  1981-08       Impact factor: 7.397

9.  Induction of liver cell injury by antibody-dependent monocyte-mediated cytotoxicity in vitro.

Authors:  Y Mizoguchi; H Tsutsui; H Sawai; T Higashimori; T Monna; S Yamamoto; S Morisawa
Journal:  Gastroenterol Jpn       Date:  1983-04

10.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.